culture he mouse breast cancer cell lines eo771  (ATCC)

Journal: bioRxiv

Article Title: Targeting CD73-A 2a R-Mediated Adenosine Signaling at the Tumor-Immune Interface Overcomes Radioresistance

doi: 10.64898/2026.05.26.727904

Figure Lengend Snippet: Intra-tumoral adenosine concentration (Mean ± SEM) in (A) human and (B) murine breast tumors and normal breast tissue quantified by LC-MS. (C) IHC staining: Magnification 200 X, Scale 100 μM and (D, E) H-score (Mean ± SEM) of CD73 and A 2a R in human normal breast tissue (epithelial cells, immune cells) and breast tumors (cancer cells, immune cells). (F) Relative expression of genes in the adenosine signaling axis in EO771 and 4T1 murine breast cancer cells compared to GAPDH by qPCR. (G) Frequency of immune cell subtypes (Mean ± SEM) in EO771 tumors by spectral flow cytometry. (H) Frequency of immune cell subtypes (Mean ± SEM) in 4T1 tumors by spectral flow cytometry. (I) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of EO771 tumors. (J) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of 4T1 tumors. (K) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in EO771 tumors quantified using spectral flow cytometry. (L) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in 4T1 tumors quantified using spectral flow cytometry. Tumors were harvested from n=10-12 mice, 25 days post-implantation. (myeloid cells (CD45 + CD11b + TCRβ - ), T cells (CD45 + CD11b - TCRβ + ), B-cells (CD45 + CD11b - CD19 + ), dendritic cells (CD45 + CD11b - CD11c + CD103 + ), NK cell – natural killer cells (CD45 + CD11b - CD11c - NK1.1 + ).

Article Snippet: Murine luminal B breast cancer cell line EO771 (ERα-, ERβ+, PR+, HER2+) and triple negative breast cancer cell line 4T1 (ER-, PR-, HER2-) was procured from ATCC.

Techniques: Concentration Assay, Liquid Chromatography with Mass Spectroscopy, Immunohistochemistry, Expressing, Flow Cytometry

Journal: bioRxiv

Article Title: Targeting CD73-A 2a R-Mediated Adenosine Signaling at the Tumor-Immune Interface Overcomes Radioresistance

doi: 10.64898/2026.05.26.727904

Figure Lengend Snippet: (A) Fold change in intra-tumoral adenosine concentrations in irradiated (8Gy x 1) EO771 tumors 12-, 24-, 48-, and 72-hours after treatment calculated with respect to adenosine concentration in unirradiated tumors. Abundance (Mean ± SEM) of (B) myeloid cells (CD45 + CD11b + ) and (C) T lymphocytes (CD45 + TCRb + ) in EO771 tumors on days 1,3,5,11 after irradiation (8Gy x 3) compared to unirradiated controls. Data are representative of two separate experiments, n=10-12 mice/group. (***) p<0.001, (****) p<0.0005. Log2 fold changes in gene expression in irradiated cells versus the corresponding unirradiated cells on day 1 (D1), 3 (D3), 5 (D5) in (D) CD45 + CD11b + cells (E) CD45 + TCRb + cells (F) CD45 - cells sorted from intra-tumoral cell suspensions (n=3 mice/group). Log2 fold changes in gene expression of adenosine signaling genes in irradiated cells versus the corresponding unirradiated cells on day 1, 3, 5 in (G) CD45 + CD11b + cells (H) CD45 + TCRb + cells (I) CD45 - cells sorted from intra-tumoral cell suspensions (n=3 mice/group).

Article Snippet: Murine luminal B breast cancer cell line EO771 (ERα-, ERβ+, PR+, HER2+) and triple negative breast cancer cell line 4T1 (ER-, PR-, HER2-) was procured from ATCC.

Techniques: Irradiation, Concentration Assay, Gene Expression

Journal: bioRxiv

Article Title: Targeting CD73-A 2a R-Mediated Adenosine Signaling at the Tumor-Immune Interface Overcomes Radioresistance

doi: 10.64898/2026.05.26.727904

Figure Lengend Snippet: (A) Adenosine concentration (Mean ± SEM) measured in cell-free supernatant from WT (EO771.lmb), ENPP1 -/- , CD73 -/- , ENPP1 -/- CD73 -/- cells grown in vitro, 18 hours after irradiation (8 Gy x 1), compared to untreated controls. (B) Tumor volume (Mean ± SEM) from WT mice bearing WT EO771, CD73 -/- EO771, or Enpp1 -/- EO771 tumors. (C, D) Tumor volume (Mean ± SEM) and survival of WT mice bearing WT EO771, CD73 -/- EO771, or Enpp1 -/- EO771 tumors irradiated (8Gy x 3) on days 13, 14, 15 post-implantation. (E, F) Tumor volume (Mean ± SEM) of orthotopic EO771 tumors implanted in wildtype (WT, C57BL6/J), CD73 -/- and A 2a R -/- A 2b R -/- mice. (G) Intra-tumoral adenosine concentration (Mean ± SEM) in paired normal murine breast tissue and EO771 tumors implanted in WT, CD73 -/- and A 2a R -/- A 2b R -/- mice. (H) Tumor volumes (Mean ± SEM) from WT (C57BL6/J), CD73 -/- , A 2a R -/- A 2b R -/- mice implanted with EO771 cells irradiated (8 Gy x 3) on days 13, 14, 15 post-implantation. Tumor volumes (Mean ± SEM) from (I) untreated and (J) radiation-treated (8Gy x 3) tumors from LysM Cre , A 2a R fl/fl , LysM Cre A 2a R fl/- , LysM Cre A 2a R fl/fl mice implanted with EO771 cells. Data are representative of two separate experiments, n=10-12 mice/group (*) p<0.05 (**), p<0.01(***), p<0.001, (****)p<0.0005.

Article Snippet: Murine luminal B breast cancer cell line EO771 (ERα-, ERβ+, PR+, HER2+) and triple negative breast cancer cell line 4T1 (ER-, PR-, HER2-) was procured from ATCC.

Techniques: Concentration Assay, In Vitro, Irradiation

Journal: bioRxiv

Article Title: Targeting CD73-A 2a R-Mediated Adenosine Signaling at the Tumor-Immune Interface Overcomes Radioresistance

doi: 10.64898/2026.05.26.727904

Figure Lengend Snippet: (A) Schematic summary of treatment schedule for EO771 or 4T1 orthotopic breast cancer model. (B) Tumor volume measurements (Mean ± SEM) beginning 8 days after EO771 implantation (n=8-10 mice/group). AB680 (quemliclustat, CD73 inhibitor), AB928 (etrumadenant, A 2a R/A 2b R antagonist), αPD1 (zimberelimab, anti-PD-1 antibody), isotype control (IgG2 antibody), tumor irradiation (RT, 8 Gy x 3; 12-, 13-, 14- days after implantation). (C) Tumor volumes from days 8-42 of irradiated mice treated in combination with isotype control, anti-PD-1, AB928 and AB680, AB928 and AB680 and anti-PD-1. (D) Spider plots of tumors from mice belonging to all treatment groups implanted with EO771 cells. (E) Slopes (Mean ± SEM) during tumor rebound period (days 32-42) from growth curves of mice belonging to irradiation and anti-PD-1, irradiation and AB680 and AB928, irradiation and AB680 and AB928 and anti-PD-1 treatment groups. (F) Tumor volume measurements (Mean ± SEM) beginning 8 days after 4T1 implantation. Data are representative of two separate experiments, n=8-10 mice/group (*) p<0.05 (**), p<0.01, (****) p<0.0005.

Article Snippet: Murine luminal B breast cancer cell line EO771 (ERα-, ERβ+, PR+, HER2+) and triple negative breast cancer cell line 4T1 (ER-, PR-, HER2-) was procured from ATCC.

Techniques: Control, Irradiation

Journal: Advanced Science

Article Title: Mapping the Tissue‐of‐Origins of Mesenchymal Stromal Cells in Injury Repair

doi: 10.1002/advs.202509533

Figure Lengend Snippet: BM‐MSC‐derived myofibroblasts or CAFs were not detected in distal tissue fibrosis or tumors. A) Confocal imaging of kidney sections from normal and UUO‐induced renal fibrotic Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. Myofibroblasts were indicated with anti‐Col1 antibody staining. B) Confocal imaging of lung sections from normal and bleomycin‐induced pulmonary fibrotic Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. Myofibroblasts were indicated with anti‐Col1 antibody staining. C) Confocal imaging of liver sections from normal and CCl 4 ‐induced liver fibrotic Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. Myofibroblasts were indicated with anti‐Col1 antibody staining. D) Confocal imaging of liver sections from normal and DDC‐induced liver fibrotic Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. Myofibroblasts were indicated with anti‐Col1 antibody staining. E–H) Quantification of the percentages of DAPI + Col1 + myofibroblasts that were ZsGreen + and tdTomato + in renal fibrosis (E), pulmonary fibrosis (F), CCl 4 ‐induced liver fibrosis (G) and DDC‐induced liver fibrosis (H). n = 5 mice from 4 independent experiments. I) Confocal imaging of E0771‐induced subcutaneous tumors from Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. Cancer associated fibroblasts (CAFs) were indicated with anti‐Col1 antibody staining. J) Confocal imaging of normal colons and AOM/DSS‐induced colorectal cancer from Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. CAFs were indicated with anti‐Col1 antibody staining. K,L) Quantification of the percentages of DAPI + Col1 + CAFs that were ZsGreen + and tdTomato + in subcutaneous tumors (K) and colorectal cancer (L). n = 3 mice from 3 independent experiments.

Article Snippet: The E0771 mouse breast cancer cell line (CRL‐3461, RRID:CVCL_GR23) was obtained from the American Tissue Type Collection (ATCC) in 2018.

Techniques: Derivative Assay, Imaging, Staining

Journal: Breast Cancer Research : BCR

Article Title: Hsp47 drives obesity-associated breast cancer progression by enhancing asporin deposition in adipose tissue

doi: 10.1186/s13058-025-02076-9

Figure Lengend Snippet: Silence of Hsp47 in adipose tissue suppresses HFD-induced mammary tumor growth. ( A - B ) Tumor growth curve of EO771 xenografts in mammary glands of control and Hsp47 Adi-KO mice under HFD (A) conditions ( n = 9). ( C ) Tumor growth curve of Wnt xenografts in mammary glands of control and Hsp47 Adi-KO mice under HFD condition ( n = 4). ( D - F ) IHC staining and quantification of cell proliferation marker Ki67 and cell apoptosis marker active-Caspase3 in tumor tissue from EO771 xenograft models in control and Hsp47 Adi-KO mice under HFD condition ( n = 6). ( G - H ) SHG imaging and quantification of collagen fiber in tumor tissues from EO771 xenograft models in control and Hsp47 Adi-KO mice under HFD condition ( n = 4). ( I ) Administration of Col003 attenuated HFD-induced weight gain in mice ( n = 5). ( J ) Tumors and tumor growth curve of mouse EO771 orthotopic xenograft models in control and Col003 treated mice (HFD) ( n = 10).( K-M ) Quantification of cell proliferation marker Ki67, active-Caspase3, and collagen deposition in EO771 tumors in control and Col003 treated mice (HFD) ( n = 6).Results are presented as mean ± SEM; * p < 0.05; ** p < 0.01; independent Student’s t test. Scar bar: 100 μm

Article Snippet: Mouse breast cancer cell lines EO771 was obtained from ATCC.

Techniques: Control, Immunohistochemistry, Marker, Imaging

Journal: Breast Cancer Research : BCR

Article Title: Hsp47 drives obesity-associated breast cancer progression by enhancing asporin deposition in adipose tissue

doi: 10.1186/s13058-025-02076-9

Figure Lengend Snippet: Asporin mediates Hsp47 function in regulating obesity and obesity-associated tumor progression. ( A ) Kaplan-Meier survival analysis showing the association of asporin expression with tumor recurrence in basal-like breast cancer. ASPN: asporin( B ) The body weight growth curve of wide type and asporin KO mice (HFD) (WT group, n = 7; KO group, n = 8). ( C ) Tumor growth curve of mouse EO771 orthotopic xenograft models in control and asporin KO mice (HFD) ( n = 11). ( D - F ) IHC staining and quantification of cell proliferation marker Ki67, and active-Caspase3 inEO771 tumor tissue from control and asporin KO mice under HFD condition ( n = 6). ( G ) Masson’s Trichome staining images and quantification of collagen deposition in E0771 tumor tissues from control and asporin KO mice under HFD condition ( n = 3)( H ) The IVIS images showing treatment of asporin protein promoted breast cancer cell growth in the decellularized mammary gland from Hsp47 Adi-KO mice ( n = 3).Results are presented as mean ± SEM; * p < 0.05; ** p < 0.01; independent Student’s t test. Scar bar: 100 μm

Article Snippet: Mouse breast cancer cell lines EO771 was obtained from ATCC.

Techniques: Expressing, Control, Immunohistochemistry, Marker, Staining